The Journal of Cosmetic Dermatology has published a case report examining hypersensitivity reactions to hyaluronic acid (HA) dermal filler after having COVID-19. In 2019, there was a 15.7 percent increase in the number of HA filler treatments performed compared to 2018, with 4 million treatments worldwide. HA filler is found natively in the mammalian tissue and is often considered to not interact or initiate a response when introduced to biological tissue. The incidence rate of having a delayed-type hypersensitivity reaction is between 0.3 percent and 4.25 percent. An exact cause of delayed-onset reactions isn't known, factors that may contribute include infections, filler properties, trauma, and injection technique, with multiple treatment episodes and links to influenza‐like illness. All patients who receive HA filler have a risk of hypersensitivity and most will have a flu-like illnesses at some point, however, this risk may be higher as COVID-19 infection rates increase. Further investigation is needed to establish the cause and effect of hypersensitivity reactions, from HA filler. For more information on the report visit www.dermatologytimes.com/view/filler-hypersensitivity-post-covid-19-illness.
Related Articles
ASDSA Launches New Patient Safety Database
Galderma Receives FDA Approval for Cheek Fillers
Galderma Receives FDA Approval For Restylane Defyne For Chin Augmentation